entertainment -WSS

entertainment

author：hotspot 2025-09-28 19:25:14 - browse：5

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Disappointing trial forces Pfizer to pivot on obesity medicine plans

WSS

Cognito secures funding to test medical device for Alzheimer's

Pediatric cancer treatments threatened by a new FDA policy

FDA drug safety: Singulair case shows systemic surveillance flaws

Congressmen charge Covid hearing ‘could have been an email’

As biotech industry slumps, bioscience job market is upside down

Time to name cancers by genetics, not organ of origin, expert says

focus

entertainment

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Commercial surrogacy can be ethical, despite pope’s claims

Bright Health sells Medicare Advantage business to Molina

How to pay for weight loss drugs and save Medicare

Psychedelics group wrestles with new pharma identity

New Ultima Genomics DNA sequencer can read genome for $100

ChatGPT in medicine: STAT answers readers' burning questions

Vertex non

Medicare proposal to cover medical devices draws a mixed reaction

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

explore

What don’t we know about an Alzheimer’s drug side effect?

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Covid misinformation case heads to Supreme Court

Congressmen charge Covid hearing ‘could have been an email’

Organ aging and disease risk measured by new blood test

General Catalyst, Summa Health deal will turn on physician buy

entertainment

explore

entertainment

hotspot